# DESCRIPTION

## FIELD OF THE INVENTION

- relate to pharmaceutical compositions

## BACKGROUND OF THE AND INVENTION

- motivate proliferative disorders
- explain protein kinase activity
- describe phosphorylation
- classify protein kinases
- discuss dysregulation of protein kinases
- introduce protein kinase inhibitors
- motivate formulation chemistry
- explain bioavailability
- describe limitations of PKIs
- discuss methods to improve dissolution
- motivate pH-dependent solubility
- discuss prior art

## SUMMARY OF THE INVENTION

- introduce pharmaceutical compositions

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate references
- define hybrid nanoparticles
- quantify crystalline PKI
- define solid dispersion particles
- define stability
- define protein kinase inhibitor
- define polymeric stabilizing and matrix-forming component
- define polymer
- define solubilizer
- define primary particles
- define supercritical fluid
- define subcritical fluid
- define area under the curve
- define apparent solubility
- define supersaturation
- define specific terms (Soluplus, TPGS, etc.)
- describe dissolution mediums (FaSSIF, FeSSIF, SGF)
- describe amorphous form
- describe inventive compositions
- define PKIs and related terms
- define water-insoluble compounds
- describe formation of hybrid nanoparticles
- describe continuous processes for generating hybrid nanoparticles
- describe precipitation methods
- describe the "Right Size system"
- describe the system components
- describe the process of producing hybrid nanoparticles
- describe the role of the polymeric stabilizing and matrix-forming component
- describe the use of modifiers
- describe the system setup and operation
- describe the particle formation function
- describe the role of pressure and temperature
- describe the concentration of PKI in the solution
- describe the properties of solvents
- describe the properties of antisolvents
- describe the selection of antisolvents
- describe the use of supercritical and subcritical fluids
- describe the conditions for supercritical and subcritical fluids
- describe the pharmaceutical composition
- describe the optional inclusion of solubilizers
- describe the distribution of solubilizers
- describe the increased dissolution rate
- describe the measurement of dissolution rate
- describe the flow through cell system
- describe the calculation of dissolution rate ratio
- describe the preferred dissolution rate ratio
- describe the measurement of dissolution rate in different solutions
- describe the solubility increase of inhibitor
- describe the measurement of solubility increase
- describe the preferred solubility increase
- describe the measurement of solubility increase in different solutions
- summarize the pharmaceutical composition
- summarize the advantages of the invention
- list polymeric stabilizing and matrix-forming components
- specify polymeric stabilizing and matrix-forming components
- provide composition with stable, amorphous hybrid nanoparticles
- characterize dissolution rate of stable, amorphous hybrid nanoparticles
- specify protein kinase inhibitor
- provide composition with stable, amorphous hybrid nanoparticles and protein kinase inhibitor
- characterize dissolution rate of stable, amorphous hybrid nanoparticles in gastric pH conditions
- characterize dissolution rate of stable, amorphous hybrid nanoparticles in intestinal pH conditions
- compare dissolution rates in gastric and intestinal pH conditions
- provide method for measuring systemically absorbed protein kinase inhibitor
- specify solubility increase of inhibitor in solution
- describe in vitro dissolution testing conditions
- specify pH range for in vitro dissolution testing
- specify solubilizer for pharmaceutical composition
- describe pharmaceutical composition with solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- specify inhibitor and polymeric stabilizing and matrix-forming component
- specify inhibitor, polymeric stabilizing and matrix-forming component, and solubilizer
- provide composition for use in therapy
- provide composition for use in treatment of proliferative disorders
- provide composition for administration during food intake
- provide method of treating proliferative disorder
- specify dose of protein kinase inhibitor
- specify administration route
- specify pharmaceutical dosage form
- specify unit dosage form
- describe oral administration
- describe parenteral administration
- describe other administration routes
- provide examples of the invention

## EXAMPLES

- introduce compositions comprising stable, amorphous hybrid nanoparticles
- describe production method of stable, amorphous hybrid nanoparticles
- describe dissolution measurement assay
- provide examples of experiments with different protein kinase inhibitors
- present results of experiments in tables
- draw conclusions from experiments

### General Description of Dissolution Measurement Assay

- describe dissolution measurement assay method
- outline sample preparation and analysis

### Example 1

- introduce nilotinib base or nilotinib HCl as protein kinase inhibitor
- describe experiments in FaSSIF and FeSSIF solutions
- present results in tables
- show solubility increase with stable, amorphous hybrid nanoparticles
- highlight improvements with polymeric stabilizing and matrix-forming components
- highlight improvements with separate solubilizer added
- discuss food effect and potential benefits

### Example 2

- introduce erlotinib HCl as protein kinase inhibitor
- describe experiments in FaSSIF and FeSSIF solutions
- present results in tables
- show solubility increase with stable, amorphous hybrid nanoparticles
- highlight improvements with polymeric stabilizing and matrix-forming components
- discuss food effect and potential benefits

### Example 3

- introduce pazopanib as protein kinase inhibitor
- describe experiments in FaSSIF and FeSSIF solutions
- present results in tables
- show solubility increase with stable, amorphous hybrid nanoparticles
- highlight improvements with polymeric stabilizing and matrix-forming components
- discuss food effect and potential benefits

### Example 4

- introduce lapatinib base or lapatinib ditosylate salt as protein kinase inhibitor
- describe experiments in FaSSIF solution
- present results in tables and discuss conclusions

### Example 5

- introduce nilotinib HCl as protein kinase inhibitor
- describe experiments in SGF solution
- present results in tables and discuss conclusions

### Example 6

- introduce gefitinib as protein kinase inhibitor
- describe experiments in FaSSIF solution
- present results in tables and discuss conclusions

### Example 7

- introduce dasatinib as protein kinase inhibitor
- describe experiments in FaSSIF solution
- present results in tables and discuss conclusions

### Example 8

- conduct experiments with sorafenib tosylate
- measure concentration of PKI after 3, 40, and 80 minutes dissolution
- describe dissolution measurement assay
- provide results in FaSSIF solution
- show solubility increase with compositions
- describe polymeric stabilizing and matrix-forming component
- add separate solubilizer to composition
- provide data of concentration of sorafenib
- provide data of % solubilized sorafenib
- provide data of AUC-mg/min/L during 80 minutes dissolution
- provide data of AUC increase of compositions
- describe experiments 138-141
- show solubility increase with dasatinib
- describe polymeric stabilizing and matrix-forming component HPMCP HP55
- add separate solubilizer Soluplus
- describe experiments 142-145
- conduct experiments with nilotinib base
- measure concentration of PKI after 3, 40, and 80 minutes dissolution
- provide results in FaSSIF solution
- show solubility increase with compositions
- describe polymeric stabilizing and matrix-forming component
- add separate solubilizer to composition
- conduct experiments with crizotinib
- measure concentration of PKI after 3, 40, and 80 minutes dissolution
- provide results in FaSSIF solution
- show solubility increase with compositions
- introduce dissolution rate measurement
- compare dasatinib with hybrid nanoparticles
- show superior dissolution rate
- introduce sorafenib tosylate measurement
- compare sorafenib tosylate with hybrid nanoparticles
- show superior dissolution rate
- introduce crizotinib measurement
- compare crizotinib with hybrid nanoparticles
- show superior dissolution rate
- introduce axitinib measurement
- compare axitinib with hybrid nanoparticles
- show superior dissolution rate
- introduce vemurafenib measurement
- compare vemurafenib with hybrid nanoparticles
- show superior dissolution rate
- introduce in vivo measurement
- describe oral administration
- describe plasma level measurement
- present results
- calculate outliers
- present pharmacokinetic parameters
- compare formulations
- show improved bioavailability
- introduce stability measurement
- describe X-ray powder diffraction
- describe thermalgravimetric analysis
- describe dynamic vapor sorption
- describe modulated differential scanning calorimetry
- describe X-ray powder diffraction

